Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.59 |
| ▸ | RAB9A | P51151 | 9/20 | 0.59 |
| ▸ | TP53 | P04637 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218108 | 0.90 | SMN1; SMN2 (0.59) | ALDH1A1KDM4EHPGDSMN1; SMN2RAB9A | |
| SCHEMBL218109 | 0.85 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDSMN1; SMN2RAB9A | |
| SCHEMBL219875 | 0.80 | KDM4E (0.61) | ALDH1A1KDM4EHPGDSMN1; SMN2RAB9A | |
| SCHEMBL217749 | 0.79 | NR4A2 (0.46) | ALDH1A1KDM4EHPGDSMN1; SMN2RAB9A | |
| SCHEMBL218076 | 0.79 | NR4A2 (0.61) | ALDH1A1 | |
| SCHEMBL219893 | 0.79 | RAB9A (0.63) | ALDH1A1KDM4EHPGDSMN1; SMN2RAB9A | |
| SCHEMBL218836 | 0.78 | NR4A2 (0.47) | ALDH1A1HPGDSMN1; SMN2RAB9AMAPT | |
| SCHEMBL2064128 | 0.78 | NR4A2 (0.59) | ALDH1A1KDM4EHPGDSMN1; SMN2RAB9A | |
| SCHEMBL218078 | 0.78 | ALDH1A1 (0.63) | ALDH1A1KDM4EHPGDSMN1; SMN2RAB9A | |
| SCHEMBL218784 | 0.75 | IRAK4 (0.41) | ALDH1A1KDM4EHPGDSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262804-B1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-12-03 | — | — | EP | claimed |
| US-8598166-B2 | Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof | SANOFI (FR) | 2013-12-03 | — | — | US | claimed |
| US-8088765-B2 | Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | claimed |
| US-20110065700-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | claimed |
| EP-2262804-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-aventis (FR) | 2010-12-22 | — | — | EP | claimed |
| WO-2009144392-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | WO | claimed |
| EP-2262804-B1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-12-03 | — | — | EP | disclosed |
| US-8598166-B2 | Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof | SANOFI (FR) | 2013-12-03 | — | — | US | disclosed |
| US-20120053202-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-03-01 | — | — | US | disclosed |
| US-8088765-B2 | Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | disclosed |
| US-20110065700-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065700-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | CYP4X1, HAX1, JAK2 | ALDH1A1 765/4885KDM4E 1360/4885HPGD 376/4885 |
| US-20120053202-A1 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | CYP4X1, HAX1, JAK2 | ALDH1A1 765/4885KDM4E 1360/4885HPGD 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.